Suzuki, Masaru
Matsumoto, Isao
Ishida, Masato
Horie, Yoshiharu
Ban, Hideyuki
Takeuchi, Wataru
Nakagawa, Shunki
Nakagawa, Tohru
Kitamura, Tetsuhisa
Muro, Shigeo
Funding for this research was provided by:
AstraZeneca K.K.
Article History
Received: 5 August 2022
Accepted: 24 March 2023
First Online: 3 April 2023
Competing interests
: MS has received honoraria from AstraZeneca K.K., Boehringer Ingelheim Japan, GlaxoSmithKline K.K., and Novartis Pharma K.K. IM, MI and YH are employees of AstraZeneca K.K. HB, WT, SN, and TN are employees of Hitachi, Ltd. TK has received honoraria from AstraZeneca KK. SM has received honoraria from AstraZeneca K.K., Boehringer Ingelheim Japan, GlaxoSmithKline K.K., Novartis Pharma K.K., Meiji Seika Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Teijin Pharma Ltd., CHEST M.I., Inc, Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Actelion Pharmaceuticals Japan Ltd., and Olympus Corporation.